Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (251-260 of 324) with videos related to

Pageof 33
Sort By:
Plos Medicine|September 30, 2010
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccinesStephen J Kent, David A Cooper, Mean Chhi Vun, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 28, 2022
RNAi-based modulation of IFN-γ signaling in skinQi Tang, Jacquelyn Sousa, Dimas Echeverria, et al.
AIDS Research and Human Retroviruses|April 12, 2003
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversionDon E Smith, Gilbert R Kaufmann, James O Kahn, et al.
The Journal of Antimicrobial Chemotherapy|February 21, 2008
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adultsJasper van der Lugt, Reshma Saskia Autar, Sasiwimol Ubolyam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trialJoseph Gathe, David A Cooper, Charles Farthing, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2010
Persistent survival of prevalent clonotypes within an immunodominant HIV gag-specific CD8+ T cell responseDavid J van Bockel, David A Price, Mee Ling Munier, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Journal of the International AIDS Society|April 21, 2018
The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90-90-90 targetsPhillip Keen, Richard T Gray, Barbara Telfer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infectionChaiwat Ungsedhapand, Preeyaporn Srasuebkul, Peter Cardiello, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2010
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapyFiona C Lampe, Daniel A Duprez, Lewis H Kuller, et al.
Pageof 33

Showing results (251-260 of 324) with videos related to

Sort By:
Pageof 33
Plos Medicine|September 30, 2010
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccinesStephen J Kent, David A Cooper, Mean Chhi Vun, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 28, 2022
RNAi-based modulation of IFN-γ signaling in skinQi Tang, Jacquelyn Sousa, Dimas Echeverria, et al.
AIDS Research and Human Retroviruses|April 12, 2003
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversionDon E Smith, Gilbert R Kaufmann, James O Kahn, et al.
The Journal of Antimicrobial Chemotherapy|February 21, 2008
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adultsJasper van der Lugt, Reshma Saskia Autar, Sasiwimol Ubolyam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trialJoseph Gathe, David A Cooper, Charles Farthing, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2010
Persistent survival of prevalent clonotypes within an immunodominant HIV gag-specific CD8+ T cell responseDavid J van Bockel, David A Price, Mee Ling Munier, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Journal of the International AIDS Society|April 21, 2018
The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90-90-90 targetsPhillip Keen, Richard T Gray, Barbara Telfer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infectionChaiwat Ungsedhapand, Preeyaporn Srasuebkul, Peter Cardiello, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2010
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapyFiona C Lampe, Daniel A Duprez, Lewis H Kuller, et al.
Pageof 33